怀越生物
NK 细胞免疫治疗开发策略及进展
演讲题目:NK 细胞免疫治疗开发策略及进展
怀越生物
Uni-Mannheim, UNC,上海医科大学；
曾任职于世界五百强医药企业先灵葆雅、德国技术合作公司（GTZ）、Praxair、复星医药集团、尚华医药集团等国内外大型药企，先后担任EVP、Project VP、R&D Director、Project Director等职务。
拥有20多年医药专业及行业管理经验，具有不同机构管理运营、研发、临床管理、投融资、市场&商业化等全流程药品开发经验。近几年重点主持、参与数个生物大分子抗体及细胞治疗项目开发，并申请了多项国内和国际专利。
Graduate from Uni-Mannheim, UNC, Shanghai Medical University.
20 + years of experience in the pharmaceutical industry, worked in MNC, Schering-Plough China, Praxair Asia, Fosun Pharma Group; Joined Shang Pharma as BD head, VP.
Drug development experience in the field of R&D, clinical trial management and market & commercial process; as well as the operational management, BD and investment and financing.
Led and participant a number of antibodies and cell therapy development, 10+patents of international (PCT) and domestic (China).
尊敬的 先生/女士
您已注册成功，注册信息及注意事项已发到联系人及参会人邮箱，请注意查收。如未收到，请联系大会联系人。
